Serum interleukin-6 is elevated in symptomatic carotid bifurcation disease

Acta Neurologica Scandinavica

Volumn 119, Issue 2, 2009, Pages 119-125

  Koutouzis, M ^a   Rallidis, L S ^b   Peros, G ^b   Nomikos, A ^a   Tzavara, V ^a   Barbatis, C ^a   Andrikopoulos, V ^a   Vassiliou, J ^c   Kyriakides, Z S ^a  

^a RED CROSS HOSPITAL   (Greece)

^b NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^c UNIVERSITY OF ATHENS   (Greece)

Author keywords

Carotid disease; Inflammation; Interleukin 6; Stroke

Indexed keywords

C REACTIVE PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; SERUM AMYLOID A; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; ATHEROSCLEROTIC PLAQUE; CAROTID ARTERY BIFURCATION; CAROTID ARTERY OBSTRUCTION; CAROTID ENDARTERECTOMY; CYTOKINE PRODUCTION; FEMALE; HUMAN; MACROPHAGE; MAJOR CLINICAL STUDY; MALE;

ADULT; AGED; AGED, 80 AND OVER; C-REACTIVE PROTEIN; CAROTID ARTERY DISEASES; CAROTID STENOSIS; ENDARTERECTOMY, CAROTID; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-1BETA; INTERLEUKIN-6; MACROPHAGES; MALE; MIDDLE AGED; SERUM AMYLOID A PROTEIN; TUMOR NECROSIS FACTOR-ALPHA;

EID: 58449093401     PISSN: 00016314     EISSN: 16000404     Source Type: Journal    
DOI: 10.1111/j.1600-0404.2008.01068.x     Document Type: Article

References (43)

1. Katsumata T, Nishiyama Y, Yamaguchi H et al. Extracranial carotid plaque is increasing in Japanese stroke patients. Acta Neurol Scand 2007 116 : 20 5.
2. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med 1999 340 : 115 26.
3. Libby P. Inflammation in atherosclerosis. Nature 2002 420 : 868 74.
4. Schonbeck U, Mach F, Sukhova GK et al. Regulation of matrix metalloproteinase expression in human vascular smooth muscle cells by T lymphocytes: a role for CD40 signaling in plaque rupture? Circ Res 1997 81 : 448 54.
5. Newby AC, Zaltsman AB. Fibrous cap formation or destruction - the critical importance of vascular smooth muscle cell proliferation, migration and matrix formation. Cardiovasc Res 1999 41 : 345 60.
6. Arbel Y, Maharshak N, Gal-Oz A et al. Lack of difference in the intimal media thickness between the left and the right carotid arteries in the young. Acta Neurol Scand 2007 115 : 409 12.
7. Wandy P, Nilsson I, Brudin L et al. Increased plasma levels of asymmetric dimethyarginine in patients with carotid stenosis: no evidence for the role of the common FABP2 A54T gene polymorphism. Acta Neurol Scand 2007 115 : 90 6.
8. Pietilä KO, Harmoinen AP, Jokiniitty J et al. Serum C-reactive protein concentrations in acute myocardial infarction and its relationship to mortality during 24 months of follow-up in patients under thrombolytic therapy. Eur Heart J 1996 17 : 1345 9.
9. Fassbender K, Rossol S, Kammer T et al. Proinflammatory cytokines in serum of patients with acute cerebral ischemia: kinetics of secretion and relation to the extent of brain damage and outcome of disease. J Neurol Sci 1994 122 : 135 9.
10. Ferrarece C, Mascarucci P, Zoia C et al. Increased cytokine release from peripheral blood cells after acute stroke. J Cereb Blood Flow Metab 1999 19 : 1004 9.
11. Smith CJ, Emsley HCA, Gavin CM et al. Peak plasma interleukin-6 and other peripheral markers of inflammation in the first week of ischaemic stroke correlate with brain infract volume, stroke severity and long-term outcome. BMC Neurol 2004 15 : 4.
12. Rallidis LS, Vikelis M, Panagiotakos DB et al. Inflammatory markers and in-hospital mortality in acute ischemic stroke. Atherosclerosis 2006 189 : 193 7.
13. Albert MA, Danielson E, Rifai N et al. Effect of statin therapy on C-reactive protein levels: the Pravastatin/CRP Evaluation (PRINCE): a randomized trial and cohort study. JAMA 2001 286 : 64 70.
14. Rezaie- Majd A, Maca T, Bucek RA et al. Simvastatin reduces expression of cytokines interleukin-6, interleukin-8, and monocyte chemoattractant protein-1 in circulating monocytes from hypercholesterolemic patients. Arterioscler Thromb Vasc Biol 2002 22 : 1194 9.
15. Lauten WB, Khan QA, Rajagopalan S et al. Usefulness of quinalapril and irbesartan to improve the anti-inflammatory response to atorvastatin and aspirin in patients with coronary heart disease. Am J Cardiol 2003 91 : 1116 9.
16. DeGrada TJ, Siren AL, Penix L et al. Increased endothelial expression of intercellular adhesion molecule-1 in symptomatic versus asymptomatic human carotid atherosclerotic plaque. Stroke 1998 29 : 1405 10.
17. Jander S, Sitzer M, Schumann R et al. Inflammation in high-grade carotid stenosis: a possible role for macrophages and T cells in plaque destabilization. Stroke 1998 29 : 1625 30.
18. Jander S, Sitzer M, Wendt A et al. Expression of tissue factor in high-grade carotid artery stenosis: association with plaque destabilization. Stroke 2001 32 : 850 4.
19. National Institute of Neurological Disorders and Stroke Stroke and Trauma Division. North American Symptomatic Carotid Endarterectomy Trial (NASCET) investigators. Clinical alert: benefit of carotid endarterectomy for patients with high-grade stenosis of the internal carotid artery. Stroke 1991 22 : 816 7.
20. Stary HC, Chandler AB, Dinsmore RE et al. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis: a report from the Committee on vascular lesions of the council on arteriosclerosis, American Heart Association. Circulation 1995 92 : 1355 74.
21. Stoll G, Bendszus M. Inflammation and atherosclerosis: novel insights into plaque formation and destabilization. Stroke 2006 37 : 1923 32.
22. Carr S, Farb A, Pearce WH et al. Atherosclerotic plaque rupture in symptomatic carotid artery stenosis. J Vasc Surg 1996 23 : 755 65.
23. Redgrave JN, Lovett JK, Gallagher PJ et al. Histologic assessment of 526 symptomatic carotid plaques in relation to the nature and timing of symptoms: the Oxford plaque study. Circulation 2006 113 : 2320 8.
24. Verhoeven B, Hellings WE, Moll FL et al. Carotid atherosclerotic plaques in patients with transient ischemic attacks and stroke have unstable characteristics compared with plaques in asymptomatic and amaurosis fugax patients. J Vasc Surg 2005 42 : 1075 81.
25. Mallat Z, Corbaz A, Scoazec A et al. Expression of interleukin-18 in human atherosclerotic plaques and relation to plaque instability. Circulation 2001 104 : 1598 603.
26. Loftus IM, Naylor AR, Goodall S et al. Increased matrix metalloproteinase-9 activity in unstable carotid plaques. A potential role in plaque disruption. Stroke 2000 31 : 40 7.
27. Eldrup N, Gronholdt ML, Sillesen H et al. Elevated matrix metalloproteinase-9 associated with stroke or cardiovascular death in patients with carotid stenosis. Circulation 2006 114 : 1847 54.
28. Schlager O, Exner M, Mlekusch W et al. C-reactive protein predicts future cardiovascular events in patients with carotid stenosis. Stroke 2007 38 : 1263 8.
29. Yamagami H, Kitagawa K, Nagai Y et al. Higher levels of interleukin-6 are associated with lower echogenicity of carotid artery plaques. Stroke 2004 35 : 677 81.
30. Smith SJ, Emsley H, Gavin CM et al. Peak plasma interleukin-6 levels and other peripheral markers of inflammation in the first week of ischaemic stroke correlate with brain infarct volume, stroke severity and long-term outcome. BMC Neurol 2004 4 : 2.
31. Hoshi T, Kitagawa K, Yamagami H et al. Relations of serum high-sensitivity C-reactive protein and interleukin-6 levels with silent brain infarction. Stroke 2005 36 : 768 72.
32. Rattazi M, Puato M, Faggin E et al. C-reactive protein and interleukin-6 in vascular disease: culprits or passive bystanders? J Hypertens 2003 21 : 1787 803.
33. Baumann H, Morella KK, Jahreis GP et al. Distinct regulation of the interleukin-1 and interleukin-6 response elements of the rat haptoglobin gene in rat and human hepatoma cells. Mol Cell Biol 1990 10 : 5967 76.
34. Kerr R, Stirling D, Ludlam CA. Interleukin-6 and haemostasis. Br J Haematol 2001 115 : 3 12.
35. Romano M, Sironi M, Toniatti C et al. Role of IL-6 and its soluble receptor in induction of chemokines and leukocyte recruitment. Immunity 1997 6 : 315 25.
36. Biswas P, Delfanti F, Bernasconi S et al. Interleukin-6 induces monocyte chemotactic protein-1 in peripheral blood mononuclear cells and in the U937 cell line. Blood 1998 91 : 258 65.
37. Rus HG, Vlaicu R, Nikulescu F. Interleukin-6 and interleukin-8 protein and gene expression in human arterial atherosclerotic wall. Atherosclerosis 1996 127 : 263 71.
38. Schieffer B, Schieffer E, Hilfiker-Kleiner D et al. Expression of angiotensin II and interleukin-6 in human coronary atherosclerotic plaques: potential implications for inflammation and plaque instability. Circulation 2000 101 : 1372 8.
39. Woods A, Brull DJ, Humphries SE et al. Genetics of inflammation and the risk of coronary artery disease. Eur Heart J 2000 21 : 1574 83.
40. Kossakowska AE, Edwards DR, Prusinkiewicz C et al. Interleukin-6 regulation of matrix metalloproteinase (MMP-2 and MMP-9) and tissue inhibitor of metalloproteinase (TIMP-1) expression in malignant non-Hodgkin's lymphomas. Blood 1999 94 : 2080 9.
41. Formato M, Farina M, Spirito R et al. Evidence of a proinflammatory and proteolytic environment in plaques from endarterectomy segments of human carotid arteries. Arterioscler Thromb Vasc Biol 2004 24 : 129 35.
42. Acalovschi D, Wiest T, Hartmann M et al. Multiple ways of regulation of the interleukin-6 system in stroke. Stroke 2003 34 : 1864 9.
43. Verhoeven BA, Moll FL, Koekkoek JA et al. Statin treatment is not associated with consistent alterations in inflammatory status of carotid atherosclerotic plaque: a retrospective study in 378 patients undergoing carotid endarterectomy. Stroke 2006 37 : 2054 60.